NTLA:NSD-Intellia Therapeutics Inc.

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 15.2

Change

+0.28 (+1.88)%

Market Cap

USD 0.61B

Volume

0.42M

Analyst Target

USD 39.79
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-3.06 (-0.76%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-15.86 (-1.75%)

USD 106.98B
MRNA Moderna Inc

-2.67 (-2.45%)

USD 38.83B
ARGX argenx NV ADR

-6.40 (-1.71%)

USD 22.08B
BNTX BioNTech SE

-1.38 (-1.57%)

USD 21.93B
GMAB Genmab AS

-1.01 (-3.55%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-0.09 (-0.06%)

USD 18.18B
RPRX Royalty Pharma Plc

+0.13 (+0.46%)

USD 18.18B
BGNE BeiGene Ltd

+4.44 (+3.08%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-9.03 (-9.90%)

USD 16.06B

ETFs Containing NTLA

XDNA 8.89 % 0.00 %

N/A

N/A
MSGR 4.67 % 0.00 %

N/A

N/A
ARKG 3.90 % 0.75 %

N/A

N/A
GNOM:SW Global X Genomics & Biote.. 3.88 % 0.00 %

-0.24 (-3.65%)

USD 6.73M
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

-0.26 (-3.65%)

CAD 0.53B
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.36% 43% F 63% D
Dividend Return N/A N/A N/A N/A F
Total Return 11.36% 43% F 63% D
Trailing 12 Months  
Capital Gain -23.81% 54% F 31% F
Dividend Return N/A N/A N/A N/A F
Total Return -23.81% 54% F 30% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 19.72% 69% C- 77% C+
Dividend Return 19.72% 68% D+ 75% C
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 43.93% 53% F 25% F
Risk Adjusted Return 44.89% 79% B- 57% F
Market Capitalization 0.61B 74% C 64% D

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -6.94 71% 79%
Price/Book Ratio 2.36 52% 41%
Price / Cash Flow Ratio -2.15 71% 84%
Price/Free Cash Flow Ratio -8.04 68% 79%
Management Effectiveness  
Return on Equity -31.70% 70% 25%
Return on Invested Capital -33.31% 71% 27%
Return on Assets -25.84% 75% 23%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector